184 related articles for article (PubMed ID: 31851762)
21. Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population.
Shukla P; Goswami S; Keizer RJ; Winger BA; Kharbanda S; Dvorak CC; Long-Boyle J
Front Pharmacol; 2020; 11():888. PubMed ID: 32714184
[TBL] [Abstract][Full Text] [Related]
22. Modelling of neutrophil dynamics in children receiving busulfan or treosulfan for haematopoietic stem cell transplant conditioning.
Solans BP; Chiesa R; Doncheva B; Prunty H; Veys P; Trocóniz IF; Standing JF
Br J Clin Pharmacol; 2020 Aug; 86(8):1537-1549. PubMed ID: 32077123
[TBL] [Abstract][Full Text] [Related]
23. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
[TBL] [Abstract][Full Text] [Related]
24. Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation.
Savic RM; Cowan MJ; Dvorak CC; Pai SY; Pereira L; Bartelink IH; Boelens JJ; Bredius RG; Wynn RF; Cuvelier GD; Shaw PJ; Slatter MA; Long-Boyle J
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1608-14. PubMed ID: 24029650
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance.
Choong E; Uppugunduri CRS; Marino D; Kuntzinger M; Doffey-Lazeyras F; Lo Piccolo R; Chalandon Y; Peters C; Daali Y; Ansari M
Ther Drug Monit; 2018 Feb; 40(1):84-92. PubMed ID: 29189665
[TBL] [Abstract][Full Text] [Related]
26. Predictive performance of a physiologically based pharmacokinetic model of busulfan in children.
Diestelhorst C; Boos J; McCune JS; Russell J; Kangarloo SB; Hempel G
Pediatr Hematol Oncol; 2014 Nov; 31(8):731-42. PubMed ID: 25007236
[TBL] [Abstract][Full Text] [Related]
27. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
Demirer T; Buckner CD; Appelbaum FR; Bensinger WI; Sanders J; Lambert K; Clift R; Fefer A; Storb R; Slattery JT
Bone Marrow Transplant; 1996 Apr; 17(4):491-5. PubMed ID: 8722344
[TBL] [Abstract][Full Text] [Related]
28. Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation.
Nava T; Kassir N; Rezgui MA; Uppugunduri CRS; Huezo-Diaz Curtis P; Duval M; Théoret Y; Daudt LE; Litalien C; Ansari M; Krajinovic M; Bittencourt H
Br J Clin Pharmacol; 2018 Jul; 84(7):1494-1504. PubMed ID: 29469189
[TBL] [Abstract][Full Text] [Related]
29. Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning.
Zao JH; Schechter T; Liu WJ; Gerges S; Gassas A; Egeler RM; Grunebaum E; Dupuis LL
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1471-8. PubMed ID: 25977229
[TBL] [Abstract][Full Text] [Related]
30. Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination.
Almog S; Kurnik D; Shimoni A; Loebstein R; Hassoun E; Gopher A; Halkin H; Nagler A
Biol Blood Marrow Transplant; 2011 Jan; 17(1):117-23. PubMed ID: 20601034
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation.
Paci A; Vassal G; Moshous D; Dalle JH; Bleyzac N; Neven B; Galambrun C; Kemmel V; Abdi ZD; Broutin S; Pétain A; Nguyen L
Ther Drug Monit; 2012 Apr; 34(2):198-208. PubMed ID: 22406655
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic Modeling and Simulation with Pharmacogenetic Insights Support the Relevance of Therapeutic Drug Monitoring for Myeloablative Busulfan Dosing in Adult HSCT.
Ben Hassine K; Seydoux C; Khier S; Daali Y; Medinger M; Halter J; Heim D; Chalandon Y; Schanz U; Nair G; Cantoni N; Passweg JR; Satyanarayana Uppugunduri CR; Ansari M
Transplant Cell Ther; 2024 Mar; 30(3):332.e1-332.e15. PubMed ID: 38081414
[TBL] [Abstract][Full Text] [Related]
33. Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?
Brooks KM; Jarosinski P; Hughes T; Kang E; Shah NN; Gall JBL; Hickstein DD; De Ravin SS; George JM; Kumar P
J Clin Pharmacol; 2018 Mar; 58(3):332-339. PubMed ID: 29238995
[TBL] [Abstract][Full Text] [Related]
34. Optimal Once-Daily Busulfan Administration in Pediatric Patients: A Simulation-Based Investigation of Intravenous Infusion Times.
Kim Y; Moon S; Rhee SJ
Drug Des Devel Ther; 2024; 18():871-879. PubMed ID: 38524879
[TBL] [Abstract][Full Text] [Related]
35. Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation.
de Castro FA; Lanchote VL; Voltarelli JC; Colturato VA; Simões BP
J Clin Pharmacol; 2013 Nov; 53(11):1205-11. PubMed ID: 23955479
[TBL] [Abstract][Full Text] [Related]
36. Characterization of drug-drug interactions on the pharmacokinetic disposition of busulfan in paediatric patients during haematopoietic stem cell transplantation conditioning.
Dunn A; Moffett BS; Ivaturi V; Gobburu JVS
Br J Clin Pharmacol; 2022 May; 88(5):2223-2235. PubMed ID: 34799882
[TBL] [Abstract][Full Text] [Related]
37. Four decades of stem cell transplantation for Fanconi anaemia in the Netherlands.
Smetsers SE; Smiers FJ; Bresters D; Sonnevelt MC; Bierings MB
Br J Haematol; 2016 Sep; 174(6):952-61. PubMed ID: 27470218
[TBL] [Abstract][Full Text] [Related]
38. Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study.
Bertholle-Bonnet V; Bleyzac N; Galambrun C; Mialou V; Bertrand Y; Souillet G; Aulagner G
Ther Drug Monit; 2007 Apr; 29(2):177-84. PubMed ID: 17417071
[TBL] [Abstract][Full Text] [Related]
39. Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling.
Admiraal R; van Kesteren C; Boelens JJ; Bredius RG; Tibboel D; Knibbe CA
Arch Dis Child; 2014 Mar; 99(3):267-72. PubMed ID: 24356807
[TBL] [Abstract][Full Text] [Related]
40. Haematopoietic cell transplantation in patients with Fanconi anaemia using alternate donors: results of a total body irradiation dose escalation trial.
MacMillan ML; Auerbach AD; Davies SM; Defor TE; Gillio A; Giller R; Harris R; Cairo M; Dusenbery K; Hirsch B; Ramsay NK; Weisdorf DJ; Wagner JE
Br J Haematol; 2000 Apr; 109(1):121-9. PubMed ID: 10848791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
